Revelation Biosciences Secures Quorum for Upcoming Special Meeting

Revelation Biosciences, Inc. has confirmed a quorum for its Special Meeting slated for December 3, 2025. The company, listed on NASDAQ as REVB, focuses on managing inflammation through its proprietary formulation, Gemini. Revelation encourages shareholders to cast their votes by December 2, 2025.

The company recently shared the successful submission of its end-of-phase 1 meeting package to the FDA. This move is part of their strategy for agency feedback on the development of Gemini as a treatment for acute kidney injury (AKI).

Financial results for the period ending September 30, 2025, were also disclosed, highlighting substantial proceeds of $9.6 million from warrant inducement and key findings from the PRIME clinical study.